Photo of Luis Isola

Luis Isola

  • PROFESSOR Medicine, Hematology and Medical Oncology
  • PROFESSOR Pediatrics
Print ProfilePrint Profile


  • Hematology

  • American Board of Internal Medicine

Clinical Focus


  • MD, University of Buenos Aires

  • Residency, Internal Medicine
    Center for Medical Education

  • Fellowship, Hematology
    Mount Sinai Hospital


    As leader of the Bone Marrow Transplantation (BMT) service at Mount Sinai, Dr. Isola promotes clinical and translational research on bone marrow transplantation. He has developed several protocols including non-ablative conditioning for allogeneic transplantation, the use of immunomagnetic technology for stem cell selection in haplo-mismatched transplantation and a combination of these two approaches for unrelated transplantation in older adults. Under his leadership the Mount Sinai BMT service performed the first mismatched transplantation using non-ablative conditioning. It is also one of only a few in the country with a FDA-approved protocol for haplo-mismatched transplantation. This is particularly important for minority populations as it is exceedingly difficult to find matched unrelated donors for patients from minorities. Also under his leadership, Mount Sinai was one of the first centers in the country to offer volunteer, unrelated peripheral blood stem cell collections for allotransplantation under the auspices of the National Marrow Donor Program. Dr. Isola has also been at the forefront in developing computerized systems for data management, capabilities that are crucial for maintaining accreditation by many organizations.


  • 1989 -
    Stratton Foundation Award for Hematology Research

  • 1988 -
    American Society of Hematology Scholar Award
    American Society of Hematology

  • 1985 -
    Research Award, 3rd. Annual Research Day of the Department of Medicine
    Mount Sinai Medical School

  • 1983 -
    Pan American Health Office Fellowship Award
    Pan American Health Organization, W.H.O.

  • 1980 -
    Price & Waterhouse House Staff Award
    Department of Internal Medicine, Center for Medical Education and Clinical Research

  • 1979 -
    Honour Diploma (Summa cum Laude)
    University of Buenos Aires Medical School


Isola L, Gordon J. Anemia in a line of transgenic mice carrying a mutant dihydrofolate-reductase gene. Dev Genet 1988; 9: 181-191.

Isola L, Gordon J. Expression of a mutant dihydrofolate reductase gene in transgenic mice. Dev Genet 1989; 10: 349-355.

Bradbury M, Isola L, Gordon J. Enzymatic amplification of a repeated DNA sequence from the mouse Y chromosome allows identification of sex of preimplantation mouse embryos. Proc Natl Acad Sci U S A 1990; 87: 4053-4057.

Isola L, Zhou SL, Kiang C, Stump D, Berk P. Expression of a plasma membrane fatty acid binding protein and a saturable fatty acid uptake mechanism in 3T3 fibroblasts after transfection with a cDNA for mitochondrial glutamic - oxaloacetic transaminase. Proc Natl Acad Sci U S A 1995;.

Berk P, Zhou SL, Kiang CL, Stump D, Bradbury M, Isola L. Uptake of long chain free fattyacids is selectively upregulated in adipocytes of Zucker rats with genetic obesity and non insulin dependent diabetes mellitus. Journal of Biological Chemistry 1997; 272: 8830-8835.

Najfeld V, Burnett W, Vlachos A, Scigliano E, Isola L, Fruchtman S. Interphase FISH analysis of sex mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant 1997; 19: 829-834.

Scaradavou A, Isola L, Rubinstein P, Galperin Y, Najfeld V, Berlin D, Gordon J, Weinberg R. A murine model for human cord blood transplantation: Near-term fetal and neonatal peripheral blood cells can achieve long-term bone marrow engraftment in sublethally irradiated adult recipients. Blood 1997; 89: 1089-1099.

Asch J, Weinberg R, Galperin Y, Kiang L, Mueller L, Jolly D, Isola L. Retroviral gene transfer into cord blood stem/progenitor cells using purified vector stocks. Am J Hematol 1998; 57: 16-23.

Skerrett D, Rosina O, Gudozowaty O, Isola L, Scigliano E, Fruchtman S. Comparative Analysis of HLA-B*8101 by Serology, Isoelectric Focusing, and Sequence-Based Typing. Human Immunology 1999; 60: 168-170.

Isola L, Scigliano E, Fruchtman S. Long Term Followup After Allogeneic G-CSF Primed Bone Marrow Transplantation. Biol Blood Marrow Transplant 2000 ; 6: 428.

Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 2014 Aug; 124(7).

Veluswamy RR, Ward SC, Yum K, Abramovitz RB, Isola LM, Jagannath S, Parekh S. Adverse drug reaction: pomalidomide-induced liver injury. Lancet 2014 Jun; 383(9935).

Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME. Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Apr; 21(4).

Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 May; 21(9).

Kim SS, Renteria AS, Steinberg A, Banoff K, Isola L. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. Cytotherapy 2014 Nov; 16(11).

Wu LM, Austin J, Valdimarsdottir H, Isola L, Rowley SD, Diefenbach MA, Cammarata M, Redd WH, Rini C. Cross-sectional study of patient-reported neurobehavioral problems following hematopoietic stem cell transplant and health-related quality of life. Psycho-oncology 2014 Dec; 23(12).

Wu LM, Austin J, Valdimarsdottir H, Isola L, Rowley SD, Diefenbach MA, Cammarata M, Redd WH, Rini C. Cross-sectional study of patient-reported neurobehavioral problems following hematopoietic stem cell transplant and health-related quality of life. Psycho-oncology 2014 Dec; 23(12).

Redd WH, Valdimarsdottir H, Wu LM, Winkel G, Byrne EE, Beltre MA, Liebman ES, Erazo T, Hayes JA, Isola L, Scigliano E, Meschian Y, Lutgendorf S, Ancoli-Israel S. Systematic light exposure in the treatment of cancer-related fatigue: a preliminary study. Psycho-oncology 2014 Dec; 23(12).

Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood 2014 May; 123(22).

Rini C, Austin J, Wu LM, Winkel G, Valdimarsdottir H, Stanton AL, Isola L, Rowley S, Redd WH. Harnessing benefits of helping others: a randomized controlled trial testing expressive helping to address survivorship problems after hematopoietic stem cell transplant. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2014 Dec; 33(12).

Shi PA, Miller LK, Isola LM. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor. Transfusion 2014 May; 54(5).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Isola did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Icahn (East) Building Floor 3 Room 310
1425 Madison Avenue
New York, NY 10029


Administrative Offices Room Suite 4F
19 East 98th Street
New York, NY 10029

Tel: 212-241-6021
Fax: 212-410-0978
Ruttenberg Treatment Center

1470 Madison Avenue
3rd Floor
New York, NY 10029

Tel: 212-241-6756
Fax: 212-410-0978
Get Directions

Office Hours:
  • Monday 9:00am - 1:00pm
  • Tuesday 1:00pm - 5:00pm
  • Wednesday 1:00pm - 5:00pm
  • Friday 1:00pm - 5:00pm
  • Spanish
Insurance Plans
  • 1199
  • Access Meicare
  • Aetna
  • Affinity
  • Amerigroup
  • AmidaCare
  • Cigna
  • Empire Blue Cross/Blue Shield
  • Fidelis
  • Group Health Insurance, Inc.
  • Health Insurance Plan (HIP)
  • Health Republic
  • HealthFirst
  • Island Group
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MultiPlan, Inc.
  • Oxford Health Plans
  • Pomco
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash